Minerva Neurosciences Collaborates with AAVnerGene for Innovative Gene Therapy in Neurological Disorders

Klotho Neurosciences Partners with AAVnerGene to Revolutionize Gene Therapy for Neurological Diseases

Klotho Neurosciences, Inc. has entered a strategic partnership with AAVnerGene Inc. to enhance its gene therapy candidates aimed at treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. This collaboration taps into AAVnerGene's advanced adeno-associated virus (AAV) manufacturing and tissue-targeting delivery technologies, which promise to streamline the production process and improve the effectiveness of Klotho's therapies. Dr. Joseph Sinkule, CEO of Klotho, articulates that leveraging AAVnerGene's proprietary systems will not only reduce manufacturing costs but also mitigate issues related to dose-dependent toxicity, a significant concern in current AAV gene therapies.

The partnership's core innovation lies in AAVnerGene’s AAVone system, which is designed to lower production costs dramatically, alongside their ATHENA platform, which enables precise targeting of tissues. This combination creates a robust synergy with Klotho’s mission to develop treatments that promote neuroprotection and healthy aging. Dr. Daozhan Yu, founder and CEO of AAVnerGene, emphasizes the pressing need for affordable treatment solutions for both rare and common neurological disorders, asserting that this partnership is a step toward addressing that need. As the collaboration unfolds, it aims to yield groundbreaking therapies that could significantly impact patient outcomes in the rapidly growing field of gene therapy.

In addition to the partnership with AAVnerGene, Klotho Neurosciences actively pursues the acquisition of technologies that enhance muscle strength and bone health, underscoring its commitment to combating age-related disorders. The company focuses on the Klotho gene, known for its association with longevity, as it seeks to develop innovative treatments that not only address neurodegenerative diseases but also slow biological aging. With advancements in clinical development for therapies KLTO-101 and KLTO-202, Klotho's initiatives are poised to transform the treatment landscape for a variety of age-related ailments, aiming to improve the quality of life for countless individuals.

Klotho’s leadership is dedicated to identifying and understanding longevity indicators, including the roles of specific genes and proteins that affect cellular health. This comprehensive approach reflects the company's commitment to pioneering research and interventions that may delay the onset of age-related diseases across multiple organ systems. As Klotho Neurosciences continues to innovate in the field of gene therapy, it positions itself as a key player in the quest for longer, healthier lives through targeted therapeutic solutions.